1,080 material Form 8-K filings that 839 companies we cover made with the SEC in May 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Exelixis reported first-quarter 2025 total revenues of $555.4 million, up from $425.2 million a year earlier, and GAAP diluted earnings per share of $0.55, up from $0.12. The company raised its 2025 total revenue guidance by $100 million, to $2.25 billion to $2.35 billion, and net product revenue guidance to $2.05 billion to $2.15 billion, citing growth in CABOMETYX demand.
Q1 2025 total revenues were $555.4 million, versus $425.2 million in Q1 2024; net product revenues were $513.3 million.
GAAP diluted EPS was $0.55 and non-GAAP diluted EPS was $0.62, versus GAAP diluted EPS of $0.12 in Q1 2024.
2025 total revenue guidance is now $2.25 billion to $2.35 billion, up from $2.15 billion to $2.25 billion.
Stock repurchases totaled $494.5 million through March 31, 2025, at an average price of $34.87 per share.
Silicon Labs reported first-quarter 2025 results for the period ended April 5, 2025, with revenue of $178 million compared with $106 million a year earlier. The GAAP loss per share narrowed to $(0.94) from $(1.77), and the company expects second-quarter revenue of $185 million to $200 million.
Revenue was $178 million for the quarter ended April 5, 2025, versus $106 million for the quarter ended March 30, 2024.
GAAP diluted loss per share was $(0.94), compared with $(1.77) a year earlier; GAAP net loss was $30 million, versus $57 million.
Non-GAAP diluted loss per share was $(0.08).
Second-quarter outlook: revenue of $185 million to $200 million; non-GAAP diluted earnings (loss) per share of $(0.01) to $0.19.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.